Tailor-made antibody therapeutics

被引：45

作者：

Chowdhury, PS ^{[1
]}

Wu, H ^{[1
]}

机构：

[1] Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA

来源：

METHODS | 2005年 / 36卷 / 01期

关键词：

therapeutic antibodies; antibody engineering; affinity maturation; effector functions; FcRn binding; antibody fragments; immunoconjugates; immunotoxins; immunocytokines; ADEPT; radio-labeled antibodies; Bi-specific antibodies; PEGylation;

D O I：

10.1016/j.ymeth.2005.01.002

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 18 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, scientists have gone beyond the traditional antibody molecules. Antibodies have been engineered in a variety of ways to meet the challenges posed by different biological settings. Described in this review is an abridged account of the different ways antibodies have been tailored to make them efficient drug molecules. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：11 / 24

页数：14

共 97 条

[71] Amino acid differences in the N-terminus of CH2 influence the relative abilities of IgG2 and IgG3 to activate complement [J].

Sensel, MG ;

Kane, LM ;

Morrison, SL .

MOLECULAR IMMUNOLOGY, 1997, 34 (14) :1019-1029

[72] Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity [J].

Shields, RL ;

Lai, J ;

Keck, R ;

O'Connell, LY ;

Hong, K ;

Meng, YG ;

Weikert, SHA ;

Presta, LG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (30) :26733-26740

[73] High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR [J].

Shields, RL ;

Namenuk, AK ;

Hong, K ;

Meng, YG ;

Rae, J ;

Briggs, J ;

Xie, D ;

Lai, J ;

Stadlen, A ;

Li, B ;

Fox, JA ;

Presta, LG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (09) :6591-6604

[74] Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice [J].

Smallshaw, JE ;

Ghetie, V ;

Rizo, J ;

Fulmer, JR ;

Trahan, LL ;

Ghetie, MA ;

Vitetta, ES .

NATURE BIOTECHNOLOGY, 2003, 21 (04) :387-391

[75]

STRAVENHANGEN J, Patent No. 2004063351A2

[76] STRUCTURAL FEATURES OF HUMAN IMMUNOGLOBULIN-G THAT DETERMINE ISOTYPE-SPECIFIC DIFFERENCES IN COMPLEMENT ACTIVATION [J].

TAO, MH ;

SMITH, RIF ;

MORRISON, SL .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :661-667

[77] THE DIFFERENTIAL ABILITY OF HUMAN IGG1 AND IGG4 TO ACTIVATE COMPLEMENT IS DETERMINED BY THE COOH-TERMINAL SEQUENCE OF THE CH2 DOMAIN [J].

TAO, MH ;

CANFIELD, SM ;

MORRISON, SL .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :1025-1028

[78] Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies [J].

Treon, SP ;

Mitsiades, C ;

Mitsiades, N ;

Young, G ;

Doss, D ;

Schlossman, R ;

Anderson, KC .

JOURNAL OF IMMUNOTHERAPY, 2001, 24 (03) :263-271

[79] Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity [J].

Tsutsumi, Y ;

Onda, M ;

Nagata, S ;

Lee, B ;

Kreitman, RJ ;

Pastan, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8548-8553

[80] Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity [J].

Umaña, P ;

Jean-Mairet, J ;

Moudry, R ;

Amstutz, H ;

Bailey, JE .

NATURE BIOTECHNOLOGY, 1999, 17 (02) :176-180

← 1 2 3 4 5 6 7 8 9 10 →